RANDOMIZED TRIAL OF CONCURRENT VERSUS SEQUENTIAL DOCETAXEL PLUS BORTEZOMIB ( PS-341) IN PLATINUM-TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): A CALIFORNIA CANCER CONSORTIUM STUDY

被引：0
|
作者：
Lara, P. N.
Longmate, J.
Argiris, A. [1 ]
Gitlitz, B. [2 ]
Mack, P. C. [3 ]
Lau, D.
Koczywas, M.
Leighl, N. B. [4 ]
Gandara, D. R. [5 ]
机构：
[1] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[2] Univ So Calif, Los Angeles, CA USA
[3] Univ Calif Davis, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[5] Univ Calif Davis, Ctr Canc, Dept Internal Med Hematol Oncol, Sacramento, CA 95817 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [1] Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezotnib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC)
    Lara, P.
    Longmate, J.
    Argiris, A.
    Gitlitz, B. J.
    Mack, P. C.
    Lau, D. H.
    Koczywas, M.
    Leighl, N. B.
    Gandara, D. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial
    Lara, Primo N., Jr.
    Longmate, Jeff
    Reckamp, Karen
    Gitlitz, Barbara
    Argiris, Athanassios
    Ramalingam, Suresh
    Belani, Chandra P.
    Mack, Philip C.
    Lau, Derick H. M.
    Koczywas, Mariana
    Wright, John J.
    Shepherd, Frances A.
    Leighl, Natasha
    Gandara, David R.
    [J]. CLINICAL LUNG CANCER, 2011, 12 (01) : 33 - 37
  • [3] Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
    Herbst, Roy S.
    Ansari, Rafat H.
    Gorbunova, V
    Manikhas, G.
    Mansoor, N. Boyd
    Thomas, E.
    Azzoli, Christopher G.
    Robert, Francisco
    Itri, Loretta M.
    Chapman, Robert
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S335 - S335
  • [4] Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: A phase I California cancer consortium trial
    Lara, Primo N., Jr.
    Koczywas, Marzana
    Quinn, David I.
    Lenz, Heinz Josef
    Davies, Angela M.
    Lau, Derick H. M.
    Gumerlock, Paul H.
    Longmate, Jeff
    Doroshow, James H.
    Schenkein, David
    Kashala, Oscar
    Gandara, David R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 126 - 134
  • [5] Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Ho, L.
    Li, T.
    Piperdi, B.
    Macapinlac, M.
    Rigas, J. R.
    Camacho, F.
    Perez-Soler, R.
    Gucalp, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Ho, Liawaty
    Piperdi, Bilal
    Elrafei, Tarek
    Camacho, Fernando J.
    Rigas, James R.
    Perez-Soler, Roman
    Gucalp, Rasim
    [J]. LUNG CANCER, 2010, 68 (01) : 89 - 93
  • [7] Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts.
    Gumerlock, PH
    Kimura, T
    Holland, WS
    Shih, CDD
    Lara, PN
    Gandara, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 652S - 652S
  • [8] Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen
    Ramlau, Rodryg
    Bennouna, Jaafar
    Tan, Eng Huat
    Biesma, Bonne
    Santoro, Armando
    Boni, Corrado
    Klein, Helmut
    Lesniewski, Krzysztof
    Mesia, Ricard
    Gatzemeier, Urlich
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S317 - S318
  • [9] Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen
    Krzakowski, M.
    Douillard, J.
    Ramlau, R.
    Jassem, J.
    Szczesna, A.
    Zatloukal, P.
    von Pawel, J.
    Hansen, O.
    Sun, X.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    Primo N. Lara
    David R. Gandara
    Jeff Longmate
    Paul H. Gumerlock
    Derick H. Lau
    Martin J. Edelman
    Regina Gandour-Edwards
    Philip C. Mack
    Valerie Israel
    James Raschko
    Paul Frankel
    Edith A. Perez
    Heinz Lenz
    James H. Doroshow
    [J]. Cancer Chemotherapy and Pharmacology, 2001, 48 : 22 - 28
12345